Alnylam price target raised to $500 from $435 at RBC Capital

RBC Capital raised the firm’s price target on Alnylam (ALNY) to $500 from $435 and keeps an Outperform rating on the shares. The latest script data came out late last week and suggests another very impressive month for Amvuttra, which looks to be is marching toward another strong beat for Q3, the analyst tells investors in a research note. Valuation remains the key debate, but the firm remains a buyer given a drug that continues to deliver and a market where the ceiling has yet to be appreciated, the firm added.